Tofacitinib Citrate Modified-Release Tablets(Taizhou Overseas Pharma)

枸橼酸托法替布多释片（越洋医药）

Report date: 2025/09/23 09:57:38

Base Information

Drug NameTofacitinib Citrate Modified-Release Tablets(Taizhou Overseas Pharma)
Drug Alias Name托法替布托西替尼托法尼布托法替尼枸橼酸托法替尼 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK1 inhibitorsTyrosine-protein kinase JAK2 inhibitorsTyrosine-protein kinase JAK3 inhibitors
TargetsTyrosine-protein kinase JAK1Tyrosine-protein kinase JAK2Tyrosine-protein kinase JAK3
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTaizhou Overseas Pharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTaizhou Overseas Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG